Colgate To Develop Anti-Cancer Toothpastes And Mouthwashes

... a wide range of molecular therapeutics that include tumor suppressors such as p53, mda-7, and FUS1. The company is in an advanced stage of developing ingn 234, a mouthwash designed to deliver the p53 tumor suppressor for the prevention of a pre-cancerous condition called Leukoplakia as well as oral cance...

INGN in Medical Technology

Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgen's INGN 241

AUSTIN, Texas--(BUSINESS WIRE)--Apr 25, 2007 - Introgen Therapeutics, Inc. (NASDAQ:INGN) today announced the publication of new preclinical data describing how an intrinsic cell survival pathway impacts the anticancer activity of INGN 241. Inhibition of this pathway, known as NF-kB, enhanced the tu...

Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241 in Patients With Advanced Solid Tumors

SEATTLE--(BUSINESS WIRE)--Jun 1, 2007 - Introgen Therapeutics, Inc. (NASDAQ:INGN) reported promising Phase 1/2 clinical data with INGN 241, the Company's novel investigational mda-7/IL-24 tumor suppressor agent, in patients with advanced solid tumors. The data (Abstract #380), which were presented...

Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference

...sented regarding Introgen's other Phase 3 product, ingn 241, indicating that inhibitors of a class of stre...eath. These pre-clinical data provide insight into ingn 241 mechanisms of action and identify future strat...and 3 clinical trials conducted worldwide. About ingn 241 ...

Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings

...ts, including those relating to Introgen's future success with its ADVEXIN, ingn 241, and ingn 007 clinical development programs. The actual results may differ from those...